Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
Top Page
Interpace Diagnostics Group
(OTC:IDXG)
Select Model
Select Model
Rating:74Outperform
Price Target:
$2.00
▲(112.77% Upside)
Action:ReiteratedDate:04/01/26
The score is driven primarily by improving fundamentals and strong recent cash flow, supported by a very low P/E and positive corporate updates (2026 growth guidance, debt-free balance sheet, potential Nasdaq uplisting). The main constraints are inconsistent top-line performance and only moderate/soft technical momentum signals.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet and conversion to an all-common equity structure materially improve financial flexibility and reduce default risk. This enables the company to allocate cash to lab automation, sales and R&D, supports a sustained operating turnaround and de-risks capital structure over the next several quarters.
Negative Factors
Uneven revenue momentum
Inconsistent top-line performance, including a revenue decline in 2025 after prior growth, raises concern about sustainable demand and market penetration. For a niche diagnostics firm, durable revenue growth is critical to absorb fixed lab costs and justify further automation or commercial investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet and conversion to an all-common equity structure materially improve financial flexibility and reduce default risk. This enables the company to allocate cash to lab automation, sales and R&D, supports a sustained operating turnaround and de-risks capital structure over the next several quarters.
Read all positive factors
Interpace Diagnostics Group (IDXG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.25M
Dividend YieldN/A
Average Volume (3M)11.58K
Price to Earnings (P/E)0.2
Beta (1Y)1.34
Revenue Growth-6.64%
EPS Growth-29.74%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.82
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap0.12
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit0.27
Enterprise Value/Ebitda1.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Interpace Diagnostics Group Business Overview & Revenue Model
Company Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic te...
Interpace Diagnostics Group Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
79
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.73M | 46.93M | 40.21M | 31.84M | 41.31M |
| Gross Profit | 24.13M | 29.93M | 23.90M | 18.23M | 17.95M |
| EBITDA | 4.08M | 8.36M | 3.84M | -2.27M | -1.33M |
| Net Income | 24.57M | 6.70M | 802.00K | -5.87M | -14.75M |
Balance Sheet | |||||
| Total Assets | 33.84M | 14.79M | 13.02M | 15.98M | 38.43M |
| Cash, Cash Equivalents and Short-Term Investments | 2.50M | 1.46M | 3.50M | 4.83M | 3.31M |
| Total Debt | 752.00K | 5.86M | 11.19M | 16.09M | 13.72M |
| Total Liabilities | 11.47M | 17.01M | 28.16M | 79.05M | 80.84M |
| Stockholders Equity | 22.36M | -2.22M | -15.14M | -63.07M | -42.42M |
Cash Flow | |||||
| Free Cash Flow | 5.47M | 3.77M | 3.32M | -8.01M | -9.07M |
| Operating Cash Flow | 5.83M | 4.65M | 3.79M | -7.69M | -8.72M |
| Investing Cash Flow | -356.00K | -876.00K | -87.00K | 6.21M | -315.00K |
| Financing Cash Flow | -4.43M | -5.81M | -5.03M | 3.00M | 8.98M |
Interpace Diagnostics Group Technical Analysis
Positive
0.94
Price Trends
1.77
Positive
1.43
Positive
1.15
Positive
Market Momentum
<0.01
Negative
63.33
Neutral
69.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Positive. The current price of 0.94 is below the 20-day moving average (MA) of 1.73, below the 50-day MA of 1.77, and below the 200-day MA of 1.15, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.33 is Neutral, neither overbought nor oversold. The STOCH value of 69.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXG.
Interpace Diagnostics Group Risk Analysis
Interpace Diagnostics Group disclosed 66 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Interpace Diagnostics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $51.25M | 0.22 | -446.40% | ― | -6.64% | -29.74% | |
54 Neutral | $17.90M | -0.14 | -245.18% | ― | -27.66% | 13.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.77M | -0.51 | -537.60% | ― | ― | 98.86% | |
44 Neutral | $6.24M | -0.85 | -197.93% | ― | 3.26% | 65.96% |
* Healthcare Sector Average
IDXG
Interpace Diagnostics Group
1.85
1.00
117.65%
NDRA
ENDRA Life Sciences
4.65
0.56
13.69%
INBS
Intelligent Bio Solutions
3.12
-11.88
-79.20%
BIAF
bioAffinity Technologies, Inc.
3.98
-22.72
-85.09%
Interpace Diagnostics Group Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial Disclosures
Interpace Diagnostics Guides 2026 Growth After Balance Sheet Cleanup
Positive
Jan 20, 2026
Interpace Biosciences reported preliminary, unaudited 2025 revenue from continuing operations of approximately $38–39 million, of which $34–35 million came from thyroid testing, reflecting 21% growth in thyroid testing revenue over 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.